Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laura C. Gittleman"'
Autor:
Laura C. Gittleman, Michael J. Silverberg, Joanna Ready, Mary Patricia Pauly, Jennifer O Lam, Scott Chamberland, Daniel G. Korn, Julia L. Marcus, Jamila H. Champsi, Jennifer B. Lai, Suk I. Seo, Leo B. Hurley, Charles P. Quesenberry, Varun Saxena, David J. Witt
Publikováno v:
Clinical Gastroenterology and Hepatology. 16:927-935
BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-w
Autor:
Daniel G. Korn, Michael J. Silverberg, Joanna Ready, Julia L. Marcus, Varun Saxena, Jennifer O Lam, Leo B. Hurley, Scott Chamberland, Charles P. Quesenberry, Mary Pat Pauly, Jamila H. Champsi, Jennifer B. Lai, Suk I. Seo, Laura C. Gittleman, David J. Witt
Publikováno v:
Public Health Reports. 133:452-460
Objectives: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data exist on factors associated with DAA initiation. Methods: We conducted a retrospective coho
Autor:
Daniel G. Korn, Michael J. Silverberg, Scott Chamberland, Varun Saxena, Suk I. Seo, David J. Witt, Jamila H. Champsi, Julia L. Marcus, Laura C. Gittleman, Jennifer B. Lai, Leo B. Hurley, Jennifer O Lam, Joanna Ready, Charles P. Quesenberry
Publikováno v:
International journal of STDAIDS. 30(7)
U.S. guidelines recommend that patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) be prioritized for HCV treatment with direct-acting antiviral agents (DAAs), but the high cost of DAAs may contribute to disparitie
Autor:
Michael J. Silverberg, Leo B. Hurley, Julia L. Marcus, Scott Chamberland, Laura C. Gittleman, Joanna Ready, David R. Witt, Suk I. Seo, Charles P. Quesenberry, Jamila H. Champsi, Jennifer B. Lai, Daniel G. Korn, Varun Saxena
Publikováno v:
Open Forum Infectious Diseases
Background The high cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may present a barrier to access, thus contributing to disparities in treatment. However, few real-world data exist on factors associated with DAA